The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 11152 malaria professionals are enjoying the free benefits of MalariaWorld today

antimalarial drug

An SR protein is essential for activating DNA repair in malaria parasites

July 28, 2021 - 13:49 -- Open Access
Author(s): 
Goyal M, Singh BK, Simantov K, Kaufman Y, Eshar S, Ron D
Reference: 
J Cell Sci. 2021 Jul 22:jcs.258572

Plasmodium falciparum, the parasite responsible for the deadliest form of human malaria, replicates within the erythrocytes of its host where it encounters numerous pressures that cause extensive DNA damage, which must be repaired efficiently to ensure parasite survival. Malaria parasites, which lost the NHEJ pathway for repairing DNA double strand breaks, have evolved unique mechanisms that enable them to robustly maintain genome integrity under such harsh conditions. However, the nature of these adaptations is unknown.

Intermittent preventive treatment for malaria in infants

July 21, 2021 - 17:07 -- Open Access
Author(s): 
Esu EB, Oringanje C, Meremikwu MM
Reference: 
Cochrane Database Syst Rev. 2021 Jul 17;7:CD011525

Intermittent preventive treatment could help prevent malaria in infants (IPTi) living in areas of moderate to high malaria transmission in sub-Saharan Africa. The World Health Organization (WHO) policy recommended IPTi in 2010, but its adoption in countries has been limited.

Antimalarial drugs-are they beneficial in rheumatic and viral diseases?-considerations in COVID-19 pandemic

July 6, 2021 - 14:27 -- Open Access
Author(s): 
Grygiel-Górniak B
Reference: 
Clin Rheumatol. 2021 Jul 3

The majority of the medical fraternity is continuously involved in finding new therapeutic schemes, including antimalarial medications (AMDs), which can be useful in combating the 2019-nCoV: coronavirus disease (COVID-19). For many decades, AMDs have been widely used in the treatment of malaria and various other anti-inflammatory diseases, particularly to treat autoimmune disorders of the connective tissue.

NOT Open Access | Host-targeted Interventions as an Exciting Opportunity to Combat Malaria

July 6, 2021 - 14:12 -- NOT Open Access
Author(s): 
Vijayan K, Wei L, Glennon EKK, Mattocks C, Bourgeois N, Staker B, Kaushansky A
Reference: 
Chem Rev. 2021 Jul 1

Terminal and benign diseases alike in adults, children, pregnant women, and others are successfully treated by pharmacological inhibitors that target human enzymes. Despite extensive global efforts to fight malaria, the disease continues to be a massive worldwide health burden, and new interventional strategies are needed. Current drugs and vector control strategies have contributed to the reduction in malaria deaths over the past 10 years, but progress toward eradication has waned in recent years.

NOT Open Access | Transgenic pyrimethamine-resistant plasmodium falciparum reveals transmission-blocking potency of P218, a novel antifolate candidate drug

July 6, 2021 - 13:04 -- NOT Open Access
Author(s): 
Posayapisit N, Pengon J, Prommana P, Shoram M, Yuthavong Y, Uthaipibull C, Kamchonwongpaisan S, Jupatanakul N
Reference: 
Int J Parasitol. 2021 Jul;51(8):635-642

Antimalarial drugs capable of targeting multiple parasite stages, particularly the transmissible stages, can be valuable tools for advancing the malaria elimination agenda. Current antifolate drugs such as pyrimethamine can inhibit replicative parasite stages in both humans and mosquitoes, but antifolate resistance remains a challenge. The lack of reliable gametocyte-producing, antifolate-resistant Plasmodium falciparum laboratory strain hinders the study of new antifolate compounds that can overcome antifolate resistance including development stages in the mosquito.

NOT Open Access | Structural analyses of the malaria parasite aminoacyl-tRNA synthetases provide new avenues for antimalarial drug discovery

June 30, 2021 - 11:28 -- NOT Open Access
Author(s): 
Chhibber-Goel J, Yogavel M, Sharma A
Reference: 
Protein Sci. 2021 Jun 28

Malaria is a parasitic illness caused by the genus Plasmodium from the apicomplexan phylum. Five plasmodial species of P. falciparum, P. knowlesi, P. malariae, P. ovale and P. vivax are responsible for causing malaria in humans. According to the World Malaria Report 2019, there were 229 million cases and ~ 0.04 million deaths of which 67% were in children below five years of age.

NOT Open Access | Bold measures to accelerate malaria elimination

June 22, 2021 - 14:07 -- NOT Open Access
Author(s): 
Price RN
Reference: 
Lancet Infect Dis. 2021 Jun 17:S1473-3099(21)00003-7

In the Greater Mekong subregion, intense drug pressure and indiscriminate use of poor-quality antimalarial drugs has led to the emergence of antimalarial resistance to all widely used drugs, including the artemisinin derivatives.

Drug-Resistant Malaria Detected in Africa Will Require Monitoring

June 16, 2021 - 15:19 -- Open Access
Author(s): 
Kuehn BM
Reference: 
JAMA. 2021 Jun 15;325(23):2335

Evidence in Africa that the malaria parasite Plasmodium falciparum has developed genetic variants that confer partial resistance to the antimalarial drug artemisinin is a warning of potential treatment failure on the horizon, a drug-resistance monitoring study suggested.

The high risk of malarial recurrence in patients with Plasmodium-mixed infection after treatment with antimalarial drugs: a systematic review and meta-analysis

May 26, 2021 - 14:40 -- Open Access
Author(s): 
Mahittikorn A, Masangkay FR, Kotepui KU, Milanez GJ, Kotepui M
Reference: 
Parasit Vectors. 2021 May 25;14(1):280

Malaria mixed infections are often unrecognized by microscopists in the hospitals, and a delay or failure to treat Plasmodium-mixed infection may lead to aggravated morbidity and increased mortality. The present study aimed to quantify the pooled proportion and risk of malarial recurrences after the treatment of Plasmodium-mixed infection. The results of the study may provide benefits in the management of Plasmodium-mixed infection in co-endemic regions.

NOT Open Access | Plasmodium malariae and Plasmodium falciparum comparative susceptibility to antimalarial drugs in Mali

May 26, 2021 - 09:43 -- NOT Open Access
Author(s): 
Dembele L, Aniweh Y, Djimde AA, et al.
Reference: 
J Antimicrob Chemother. 2021 May 22:dkab133

To evaluate Plasmodium malariae susceptibility to current and lead candidate antimalarial drugs.

Pages

Subscribe to RSS - antimalarial drug